| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
OVA (241-270) TFA contains multiple T cell epitopes that can be recognized by both CD4+ and CD8+ T cells after processing. In the context of antigen-presenting cells, this peptide is taken up, processed, and presented on MHC class I and class II molecules. It activates OVA-specific T cells (particularly OT-I and OT-II T cells) in a non-specific manner. This peptide enables the study of T cell activation, proliferation, and cytokine production. It is a non-specific activator of cytotoxic T lymphocytes (CTLs). It is a fragmented peptide of the OVA antigen. This peptide plays an important role in the immune system by activating CTLs, which are specialized immune cells that identify and kill infected or abnormal cells.
|
|---|---|
| ln Vitro |
In vitro, OVA (241-270) TFA is processed and presented to T cells after uptake by dendritic cells (DCs) or other antigen-presenting cells (APCs). Unlike the minimal epitope peptide OVA (257-264) which directly loads onto MHC class I, the longer OVA (241-270) peptide requires intracellular processing. In cell-based assays, bone marrow-derived dendritic cells (BMDCs) are pulsed with OVA (241-270) (10-100 microg/mL) for 2-4 hours, washed, and cocultured with OVA-specific CD8+ T cells (OT-I) or CD4+ T cells (OT-II). T cell activation is measured by CD69 expression, proliferation (CFSE dilution), or cytokine production (IFN-gamma, IL-2). The peptide can elicit responses from both CD4+ and CD8+ T cells due to the presence of overlapping epitopes.
|
| ln Vivo |
In vivo, OVA (241-270) TFA can be used to prime T cell responses in C57BL/6 mice. Mice are immunized subcutaneously or intraperitoneally with OVA (241-270) peptide (50-200 microg per mouse) emulsified in Complete Freund's Adjuvant (CFA) or mixed with other adjuvants. Alternatively, the peptide can be delivered in liposomes or nanoparticles. After 7-14 days, splenocytes or lymph node cells are harvested and restimulated ex vivo with the peptide. T cell responses are analyzed by intracellular cytokine staining, ELISpot, or cytotoxicity assays. The longer peptide may be processed differently than the minimal epitope, providing insights into antigen processing pathways. The peptide also contributes to the induction of delayed-type hypersensitivity (DTH) in BALB/c mice.
|
| Enzyme Assay |
OVA (241-270) TFA is not used in cell-free enzyme assays. For receptor binding assays, it is not directly used because the peptide requires processing. However, a T cell hybridoma activation assay can be performed to study antigen presentation. BMDCs or spleen-derived APCs are seeded in 96-well plates (1×10⁵ cells/well). OVA (241-270) TFA (0.1-100 microM) is added and incubated for 2-4 hours. After washing, OVA-specific T cell hybridomas (e.g., B3Z for CD8+ response or other hybridomas for CD4+ response) are added at 1×10⁵ cells/well. After 18-24 hours, activation is measured by IL-2 production (ELISA) or lacZ expression (using a colorimetric substrate for beta-galactosidase, e.g., CPRG). The EC50 for T cell activation is calculated from the dose-response curve.
|
| Cell Assay |
For T cell proliferation assays, CD8+ T cells are isolated from OT-I transgenic mice (or CD4+ T cells from OT-II mice). Splenocytes are enriched using magnetic bead-based negative selection. Isolated T cells are labeled with CFSE (5 microM, 10 min, 37degC). APCs (irradiated splenocytes or BMDCs) are incubated with OVA (241-270) TFA (1-100 microg/mL) for 2 hours, then washed extensively to remove free peptide. CFSE-labeled T cells are added to APCs at a 1:1 ratio. After 72 hours, T cell proliferation is measured by CFSE dilution using flow cytometry. Alternatively, T cell activation is assessed by CD69 and CD25 expression at 24 hours. For cytokine production, culture supernatants are collected at 48 hours and analyzed by ELISA for IFN-gamma, IL-2, TNF-alpha (for CD8+), and IL-4, IL-5, IL-13 (for CD4+ Th2 responses). Female BALB/c mice are used for DTH studies. OVA (241-270) TFA is involved in the generation and development of delayed-type hypersensitivity reactions.
|
| Animal Protocol |
For immunization studies, female C57BL/6 mice (6-8 weeks old, n=5-8 per group) are immunized subcutaneously at the base of the tail or in the flank with OVA (241-270) TFA (100 microg per mouse) emulsified in CFA (1:1 volume). A control group receives CFA alone. On day 7, mice receive a booster immunization with the same dose of peptide in Incomplete Freund‘s Adjuvant (IFA). On day 14, spleens and draining lymph nodes (inguinal and popliteal) are harvested. Single-cell suspensions are prepared. For antigen-specific recall responses, 2×10⁵ splenocytes are cultured with OVA (241-270) peptide (0-100 microg/mL) for 48-72 hours. Supernatants are collected for cytokine measurement by multiplex assay or ELISA. Alternatively, an ELISpot assay is performed to enumerate IFN-gamma or IL-4 spot-forming cells. For DTH studies, BALB/c mice are primed with OVA (241-270) (100 microg in CFA, sc). On day 7, mice are challenged intradermally in the footpad or ear with the peptide (50 microg in 50 microL PBS). DTH response is measured as footpad swelling (using a caliper) or ear thickness at 24 hours. This peptide is important for DTH responses.
|
| ADME/Pharmacokinetics |
The TFA salt has a molecular weight of 3535.92 Da with formula C156H247F3N34O53S1. The lyophilized powder should be stored at -80degC (2 years) or -20degC (1 year) in sealed containers away from moisture. For solution storage, it should be kept at -80degC for 6 months or -20degC for 1 month under sealed, moisture-protected conditions. The peptide is typically soluble in DMSO (10-20 mg/mL) and PBS. The TFA salt enhances solubility. Working solutions should be prepared fresh or stored in small aliquots to avoid repeated freeze-thaw cycles. Avoid prolonged exposure to light and moisture. The compound appears as a white or off-white solid.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic use. No specific toxicity data is available for this peptide. At concentrations used for T cell assays (1-100 microg/mL), the peptide is generally non-toxic. The TFA counterion may be cytotoxic at high concentrations (e.g., >0.1% v/v) but is diluted to safe levels in cell culture (final TFA concentrations <0.01%). Standard laboratory safety practices should be followed, including the use of PPE (gloves, lab coat, safety glasses). Avoid inhalation of powder. The peptide is not intended for in vivo use in humans. Animals should be handled under approved institutional guidelines. This peptide is a research tool, not a clinical drug.
|
| References |
[1]. Ming-Chieh Yang, et al. Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci. 2016 Mar 3;6:17.
|
| Additional Infomation |
OVA (241-270) is a 30-mer peptide derived from ovalbumin that contains multiple overlapping epitopes recognized by both CD4+ and CD8+ T cells. It is a valuable research tool for studying antigen processing, presentation, and T cell immunity. It is often used as a model antigen for investigating MHC class I and class II antigen presentation pathways. This peptide is a non-specific CTL peptide, meaning it can activate CTLs in an antigen-specific but non-MHC-restricted manner after processing. It is used in many immunological studies, including vaccine research, immune tolerance mechanisms, autoimmune disease models, and cancer immunotherapy. The peptide is derived from the OVA antigen. This product is not a drug and is not FDA-approved. Supplier information must not be included.
|
| Molecular Formula |
C156H247F3N34O53S1
|
|---|---|
| Related CAS # |
OVA (241-270);2648610-97-1
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~28.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (0.71 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (0.71 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
